Maximum quantity allowed is 999
Please select the quantity
CAS RN: 82159-09-9 | Product Number: E0906
Epalrestat
Purity: >98.0%(T)(HPLC)
Synonyms:
Product Documents:
Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time | Shipping Information |
---|---|---|---|---|---|
1G |
₩87,000
|
17 | 19 | Contact Us | |
5G |
₩273,800
|
8 | ≥40 | Contact Us |
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
Product Number | E0906 |
Purity / Analysis Method | >98.0%(T)(HPLC) |
Molecular Formula / Molecular Weight | C__1__5H__1__3NO__3S__2 = 319.39 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
CAS RN | 82159-09-9 |
Reaxys Registry Number | 4236712 |
PubChem Substance ID | 172089065 |
Merck Index (14) | 3605 |
MDL Number | MFCD00865484 |
Specifications
Appearance | Light yellow to Amber to Dark green powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Neutralization titration) | min. 98.0 % |
Melting point | 222.0 to 226.0 °C |
Properties (reference)
Melting Point | 224 °C |
GHS
Pictogram | |
Signal Word | Danger |
Hazard Statements | H300 : Fatal if swallowed. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
Related Laws:
RTECS# | XJ5131855 |
Transport Information:
UN Number | UN2811 |
Class | 6.1 |
Packing Group | II |
H.S.code* | 2934.10-000 |
Application
Aldose Reductase (AR) Inhibitor
References
- Effects of a new aldose reductase inhibitor on various tissues in vitro
- H Terashima, K Hama, R Yamamoto, M Tsuboshima, R Kikkawa, I Hatanaka, Y Shigeta, J. Pharmacol. Exp. Ther. 1984, 229, 226.
- Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients
- An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-β and protein kinase C activity in cultured human mesangial cells
- Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase
- Aldose reductase structures: Implications for mechanism and inhibition
- Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy
- M. A. Ramirez, N. L. Borja, Pharmacotherapy 2008, 28, 646.
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.